Diagnosis and treatment of inflammatory bowel disease
Stephan R. Targan, Santa Monica, CA (US); Marla C. Dubinsky, Los Angeles, CA (US); Carol J. Landers, Los Angeles, CA (US); Ling Mei, Pasadena, CA (US); Jerome I. Rotter, Los Angeles, CA (US); and Kent D. Taylor, Ventura, CA (US)
Assigned to CEDARS-SINAI MEDICAL CENTER, Los Angeles, CA (US)
Filed by CEDARS-SINAI MEDICAL CENTER, Los Angeles, CA (US)
Filed on Jan. 28, 2022, as Appl. No. 17/588,089.
Application 13/410,881 is a division of application No. 12/599,549, granted, now 8,153,443, issued on Apr. 10, 2012, previously published as PCT/US2008/063202, filed on May 9, 2008.
Application 17/588,089 is a continuation of application No. 16/683,141, filed on Nov. 13, 2019, granted, now 11,268,149.
Application 16/683,141 is a continuation of application No. 14/726,343, filed on May 29, 2015, granted, now 10,544,459, issued on Jan. 28, 2020.
Application 14/726,343 is a continuation in part of application No. 11/720,785, abandoned, previously published as PCT/US2005/044335, filed on Dec. 8, 2005.
Application 14/726,343 is a continuation in part of application No. 12/527,376, abandoned, previously published as PCT/US2008/054033, filed on Feb. 14, 2008.
Application 14/726,343 is a continuation in part of application No. 12/529,106, abandoned, previously published as PCT/US2008/056103, filed on Mar. 6, 2008.
Application 14/726,343 is a continuation in part of application No. 13/124,311, abandoned, previously published as PCT/US2009/061698, filed on Oct. 22, 2009.
Application 14/726,343 is a continuation in part of application No. 13/410,881, filed on Mar. 2, 2012, abandoned.
Application 14/726,343 is a continuation in part of application No. 12/196,505, filed on Aug. 22, 2008, abandoned.
Application 12/196,505 is a continuation of application No. 12/032,442, filed on Feb. 15, 2008, abandoned.
Claims priority of provisional application 61/107,590, filed on Oct. 22, 2008.
Claims priority of provisional application 60/917,254, filed on May 10, 2007.
Claims priority of provisional application 60/893,308, filed on Mar. 6, 2007.
Claims priority of provisional application 60/890,429, filed on Feb. 16, 2007.
Claims priority of provisional application 60/889,806, filed on Feb. 14, 2007.
Claims priority of provisional application 60/634,339, filed on Dec. 8, 2004.
Prior Publication US 2022/0290235 A1, Sep. 15, 2022
1. A process for predicting IBD susceptibility in a subject, comprising:
providing a sample from the subject;
assaying the sample to detect risk and/or protective variants in genes selected from the group consisting of: CARD 8, TLR8, TLR2 and JAK3;
assaying the sample to detect risk serological factors selected from the group consisting of: anti-CBirl, pANCA, anti-OmpC, ASCA and anti-I2; and
determining that the subject has increased susceptibility to IBD if one or more risk variants and/or risk serological factors are present and the protective variants are absent or determining that the subject has a decreased susceptibility to IBD if one or more protective variants are present and the risk variants and/or risk serological factors are absent,
wherein IBD comprises Crohn's disease (CD) and ulcerative colitis (UC).